Immune signatures to affect overall survival (OS) and response to bevacizumab (Bev) or cetuximab (Cet) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance).

被引：0

作者：

Innocenti, Federico

Yazdani, Akram

Qu, Xueping

Ou, Fang-Shu

Van Buren, Scott

Kabbarah, Omar

Blanke, Charles David

Venook, Alan P.

Lenz, Heinz-Josef

Vincent, Benjamin Garrett

机构：

[1] Univ N Carolina, Chapel Hill, NC 27515 USA

[2] Genentech Inc, San Francisco, CA USA

[3] Mayo Clin, Rochester, MN USA

[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[5] Univ Calif San Francisco, San Francisco, CA 94143 USA

[6] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA

[7] UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

来源：

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.3515

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3515

引用

页数：2